Publication at First Faculty of Medicine |
2012
Abstract
Cardiovascular complications are the major cause of morbidity and mortality of pacients with type 2 diabetes mellitus. This is why the major aim of the complex treatment of these patiens is to decrese thein total cardiovascular risk.
Out of recently introduced antidiabetic therapies experimental and smaller clinical studies suggest a very good potential for incretin-based therapies i.e. gliptins or glucagon-like peptide 1 agonists.